Teva Pharmaceuticals
TEVA
507 hedge funds and large institutions have $11.2B invested in Teva Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 98 funds opening new positions, 129 increasing their positions, 209 reducing their positions, and 123 closing their positions.
44% more funds holding in top 10
Funds holding in top 10: 9 → 13 (+4)
18% more capital invested
Capital invested by funds: $9.47B → $11.2B (+$1.75B)
5.36% more ownership
Funds ownership: 53.04% → 58.39% (+5.4%)
5% less funds holding
Funds holding: 535 → 507 (-28)
20% less first-time investments, than exits
New positions opened: 98 | Existing positions closed: 123
23% less call options, than puts
Call options by funds: $617M | Put options by funds: $807M
38% less repeat investments, than reductions
Existing positions increased: 129 | Existing positions reduced: 209
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$431M |
| 2 |
Berkshire Hathaway
Omaha,
Nebraska
|
+$284M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$186M |
| 4 |
BC
Brahman Capital
New York
|
+$150M |
| 5 |
HCM
Highfields Capital Management
Boston,
Massachusetts
|
+$138M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$193M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$150M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$82M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$76.1M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$63.9M |
TEVA Hedge Fund Activity: Q4 2017 in Review
507 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q4 2017, worth a combined $11.2B — up 18% from $9.47B a quarter earlier.
Sellers outnumbered buyers: 123 funds closed out of TEVA and 98 opened new positions — a net loss of 25 holders — while 209 trimmed existing stakes and 129 added.
The largest buyer was Capital Research Global Investors, adding an estimated $431M. The largest seller was Bank of New York Mellon, cutting an estimated $193M.
- 507 institutional investors held Teva Pharmaceuticals (TEVA) as of Q4 2017, down from 535 in Q3 2017.
- Funds reported $11.2B of Teva Pharmaceuticals stock for Q4 2017, up 18% quarter-over-quarter.
- 98 funds opened new Teva Pharmaceuticals positions in Q4 2017 and 123 closed out, a net change of -25 holders.
- The largest Teva Pharmaceuticals buyer in Q4 2017 was Capital Research Global Investors, an estimated $431M added.
- The largest Teva Pharmaceuticals seller in Q4 2017 was Bank of New York Mellon, an estimated $193M sold.
Based on aggregated 13F filings for Q4 2017.